Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Etakafusp Alfa · AB-248

Fusion protein · Immune activation, directed at CD8 beta chain (CD8B) · developed by Amgen

Phase 1 Most advanced trial
AMGN Developer
1 Registered trials

What is Etakafusp Alfa?

Etakafusp alfa is a recombinant fusion protein comprising a humanized IgG1 antibody targeting CD8B linked to an affinity-attenuated IL-2 mutein. It binds CD8+ T-cells and activates IL-2R signaling to enhance cytotoxic T-lymphocyte responses against tumor cells while minimizing activation of NK cells and regulatory T-cells. It is studied in extensive-stage small cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AB-248
Drug type
Fusion protein
Targets
CD8 beta chain (CD8B), IL-2 receptor (IL2RA) (secondary target), IL-2 receptor beta (IL2RB) (secondary target)
Mechanism
Immune activation, directed at CD8 beta chain (CD8B)
Pathways
IL-2R signaling, CD8+ T-cell activation
Therapy area
Immunology, Oncology
Developer
Amgen (AMGN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
5Y27P3LNU6

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07037758 Phase 1 Extensive Stage Small Cell Lung Cancer Recruiting AMGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Extensive Stage Small Cell Lung Cancer

More from Amgen

Apremilast FDA approved Blinatumomab FDA approved Carfilzomib FDA approved Denosumab FDA approved Erenumab FDA approved Evolocumab FDA approved Pegloticase FDA approved Prednisone FDA approved Romiplostim FDA approved Romosozumab FDA approved Sotorasib FDA approved Tarlatamab FDA approved

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AMGN page.

Follow AMGN, the company behind Etakafusp Alfa

See AMGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AMGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.